Abstract:Isocitric dehydrogenase (IDH)-wild type diffuse gliomas, which have a poorer prognosis than their IDH-mutant counterparts, are also accompanied with high heterogeneity. Here, we aimed to identify the key biological processes associated with the three groups of IDH-wild type diffuse gliomas in 323 patients. By The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) update 3 recommendation, the three groups are Group A, diffuse astrocytic glioma, World Health Organization (WHO) grade II/III; Group B, diffuse astrocytic glioma, with one (or more) of the three genetic alterations: TERT promoter mutation, EGFR gene amplification, gain of chromosome 7 combined with loss of chromosome 10, WHO grade IV; and Group C, glioblastoma, WHO grade IV. Consistent with their histologic and genetic molecular features, we successfully identified that biological activities associated with "cell cycle" and "cell mitosis" are significantly elevated in Group B compared with Group A; microenvironment-related hallmarks "angiogenesis" and "hypoxia," and biological processes of "extracellular matrix," "immune response," and "positive regulation of transcriptional activities" were more enriched in Group C than Group B. We also constructed a nine-gene signature from differentially expressed genes among the three groups to further stratify the WHO grade IV gliomas (Groups B and C) whose survival cannot be clearly stratified by current classification systems. This signature was an independent prognosis factor for WHO grade IV gliomas and had better prognostic value than other known factors in both training and validation dataset. In addition, the signature risk score was positively correlated with the amount of infiltrated immune cells, expression of immune checkpoints, and the genes enriched in biological processes of "immune response," "cell cycle," and "extracellular matrix." The bioinformatic analysis results were also validated by immunohistochemistry and patient-derived cell proliferation assay. Overall, our findings revealed the key biological processes underlying the new classifications of IDH-wild type diffuse glioma. Meanwhile, we constructed a signature, which could properly stratify the prognosis, cell proliferation activates, extracellular matrix-mediated biological activities, and immune-microenvironment of IDH-wild type WHO grade IV gliomas.

Adult IDH Wild-Type Lower-Grade Gliomas Should Be Further Stratified

Isocitrate Dehydrogenase 1/2 Wildtype Adult Astrocytoma with WHO Grade 2/3 Histological Features: Molecular Re-Classification, Prognostic Factors, Clinical Outcomes

IDH Mutant Lower Grade (WHO Grades II/III) Astrocytomas Can Be Stratified for Risk by CDKN2A, CDK4 and PDGFRA Copy Number Alterations.

IDH-1R132H Mutation Status in Diffuse Glioma Patients: Implications for Classification.

Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design

Integrated Analysis of the Clinical and Molecular Characteristics of IDH Wild-Type Gliomas in the Chinese Glioma Genome Atlas

Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas

Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma

Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.

Mismatch Repair Proteins PMS2 and MLH1 Can Further Refine Molecular Stratification of IDH-mutant Lower Grade Astrocytomas

IDH Clonal Heterogeneity Segregates a Subgroup of Non‐1p/19q Codeleted Gliomas with Unfavourable Clinical Outcome

Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System

Molecular Landscape of IDH-wild-type, H3-wild-type Glioblastomas of Adolescents and Young Adults.

Biomarker-based Prognostic Stratification of Young Adult Glioblastoma

Local and Systemic Effects of IDH Mutations on Primary Glioma Patients.

GENE-13. GENOMIC AND RADIOMIC LANDSCAPE OF IDH WILDTYPE-TERT PROMOTER MUTATION IN LOWER-GRADE GLIOMAS

Path-16. Molecular Alterations In Idh-Mutant Astrocytoma: A Multi-Institutional Retrospective Study

MPTH-24COMBINATION GENETIC SIGNATURE STRATIFIES PROGNOSIS IN LOWER-GRADE GLIOMAS BUT IDH STATUS ALONE DOES NOT SUPERSEDE HISTOLOGIC GRADES

Classification Based on Mutations of TERT Promoter and IDH Characterizes Subtypes in Grade II/III Gliomas.

New Molecular Prognostic Factors of Adult Diffuse Lower-Grade Gliomas in Post-2016 Molecular Era: a Retrospective Analysis from Single Center